Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs AR 101 (Primary) ; Dupilumab (Primary)
  • Indications Peanut hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 15 Oct 2018 Status changed from not yet recruiting to recruiting, according to an Aimmune Therapeutics media release.
    • 21 Sep 2018 Status changed from planning to not yet recruiting.
    • 08 May 2018 According to an Aimmune Therapeutics media release, Regeneron / Sanofi expects to initiate this Phase 2 trial of AR101 by year end 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top